Abstract
Kidney disease is becoming a global public health issue. Acute kidney injury (AKI) and chronic kidney disease (CKD) have serious adverse health outcomes. However, there is no effective therapy to treat these diseases. Lactoferrin (LF), a multi-functional glycoprotein, is protective against various pathophysiological conditions in various disease models. LF shows protective effects against AKI and CKD. LF reduces markers related to inflammation, oxidative stress, apoptosis, and kidney fibrosis, and induces autophagy and mitochondrial biogenesis in the kidney. Although there are no clinical trials of LF to treat kidney disease, several clinical trials and studies on LF-based drug development are ongoing. In this review, we discussed the possible kidney protective mechanisms of LF, as well as the pharmacological and therapeutic advances. The evidence suggests that LF may become a potent pharmacological agent to treat kidney diseases.
| Original language | English |
|---|---|
| Pages (from-to) | 1-13 |
| Number of pages | 13 |
| Journal | Korean Journal of Physiology and Pharmacology |
| Volume | 26 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 2022 |
Bibliographical note
Funding Information:This work was funded by the National Research Foundation (No. 2020R1I1A1A01072879 and 2015H1D3A1062189) and the Brain Pool program was funded by the Ministry of Science and ICT through the National Research Foundation (No. 2020H1D3A2A02110924), Republic of Korea.
Publisher Copyright:
© 2022 Korean Physiological Soc. and Korean Soc. of Pharmacology. All rights reserved.